FDA to assess Teva's biologics application for Neutroval

02/2/2010 | Reuters

The FDA will evaluate Teva Pharmaceutical Industries' biologics-license application for XM02, a white blood cell booster and a follow-on version of Amgen's Neupogen, the company announced. In its filing, Teva stated that it plans to market the drug as Neutroval.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC